Celldex Therapeutics, Inc. (CLDX)Healthcare | Biotechnology | Hampton, United States | NasdaqCM
39.12 USD
-1.34
(-3.312%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 39.12 |
Hot Take ↕ | Aug. 22, 2026, 3:58 a.m. EDT
The investment case for Celldex Therapeutics is currently defined by a stark disconnect between optimistic analyst targets and a deteriorating business reality. While the balance sheet remains technically healthy with minimal debt and ample cash reserves, the company is hemorrhaging cash with negative operating flows and has suffered a catastrophic 97% collapse in revenue year-over-year. The multi-year price trajectory confirms this structural failure, showing a 61% decline over the last nine years, capped recently by another 36% drop. The market has correctly priced this as a value trap; despite the 'strong buy' analyst consensus driven by potential future approvals, the lack of current profitability and shrinking top-line makes holding the stock highly risky. Options data reinforces this bearish sentiment, with traders aggressively buying deep out-of-the-money puts to hedge against further downside while offering little support for a sustained upward move. Until there is concrete evidence of revenue recovery or a successful product launch that reverses the multi-year decline, the long-term outlook remains deeply bearish. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.177031 |
| AutoETS | 0.177060 |
| MSTL | 0.178068 |
| AutoTheta | 0.196529 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 41% |
| H-stat | 8.98 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.250 |
| Excess Kurtosis | -0.59 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.686 |
| Revenue per Share | 0.002 |
| Market Cap | 3,072,075,264 |
| Forward P/E | -9.40 |
| Beta | 0.84 |
| Website | https://www.celldex.com |
As of Aug. 22, 2026, 3:58 a.m. EDT: Speculators are heavily positioned for downside protection, evidenced by massive open interest in out-of-the-money puts (strikes 20-30) across multiple expirations, creating significant resistance walls. Conversely, call activity is sparse and concentrated near the money, with notable volume spikes at strikes slightly above current price suggesting a speculative attempt to catch a bounce rather than a conviction bet on a major rally. Implied volatility is elevated on deep out-of-the-money puts, indicating fear of further declines.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.8340888 |
| Address1 | Perryville III Building |
| Address2 | Suite 220 53 Frontage Road |
| All Time High | 3,375.0 |
| All Time Low | 1.5 |
| Ask | 44.74 |
| Ask Size | 1 |
| Audit Risk | 4 |
| Average Daily Volume10 Day | 766,920 |
| Average Daily Volume3 Month | 1,040,288 |
| Average Volume | 1,040,288 |
| Average Volume10Days | 766,920 |
| Beta | 0.837 |
| Bid | 33.62 |
| Bid Size | 1 |
| Board Risk | 1 |
| Book Value | 9.103 |
| City | Hampton |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 5 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 39.12 |
| Current Ratio | 11.821 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 40.57 |
| Day Low | 39.04 |
| Debt To Equity | 0.686 |
| Display Name | Celldex Therapeutics |
| Dividend Date | 1,549,843,200 |
| Earnings Timestamp End | 1,794,254,400 |
| Earnings Timestamp Start | 1,794,254,400 |
| Ebitda | -322,432,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -7.644 |
| Enterprise To Revenue | 15,598.873 |
| Enterprise Value | 2,464,621,824 |
| Eps Current Year | -4.10626 |
| Eps Forward | -4.1624 |
| Eps Trailing Twelve Months | -4.35 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 908 454 1911 |
| Fifty Day Average | 38.2712 |
| Fifty Day Average Change | 0.84880066 |
| Fifty Day Average Change Percent | 0.022178575 |
| Fifty Two Week Change Percent | 83.40888 |
| Fifty Two Week High | 45.14 |
| Fifty Two Week High Change | -6.0200005 |
| Fifty Two Week High Change Percent | -0.13336289 |
| Fifty Two Week Low | 21.77 |
| Fifty Two Week Low Change | 17.349998 |
| Fifty Two Week Low Change Percent | 0.7969682 |
| Fifty Two Week Range | 21.77 - 45.14 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 516,547,800,000 |
| Float Shares | 73,018,329 |
| Forward Eps | -4.1624 |
| Forward P E | -9.398424 |
| Free Cashflow | -133,080,496 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 198 |
| Fullday Change | -1.34 |
| Fullday Change Percent | -3.31191 |
| Fullday Price | 39.12 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.0 |
| Gross Profits | -278,648,992 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00271 |
| Held Percent Institutions | 1.10296 |
| Implied Shares Outstanding | 78,529,532 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ir Website | http://www.avantimmune.com/ |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,549,843,200 |
| Last Split Factor | 1:15 |
| Long Business Summary | Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey. |
| Long Name | Celldex Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 3,072,075,264 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_9620565 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -300,548,992 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 3,177,304,864 |
| Number Of Analyst Opinions | 15 |
| Open | 40.33 |
| Operating Cashflow | -235,566,000 |
| Operating Margins | -3,664.682 |
| Overall Risk | 1 |
| Payout Ratio | 0.0 |
| Phone | 908 200 7500 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 39.12 |
| Post Market Time | 1,787,959,804 |
| Previous Close | 40.46 |
| Price Eps Current Year | -9.526917 |
| Price Hint | 2 |
| Price To Book | 4.2974844 |
| Price To Sales Trailing12 Months | 19,443.514 |
| Profit Margins | 0.0 |
| Quick Ratio | 11.705 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -1.34 |
| Regular Market Change Percent | -3.31191 |
| Regular Market Day High | 40.57 |
| Regular Market Day Low | 39.04 |
| Regular Market Day Range | 39.04 - 40.57 |
| Regular Market Open | 40.33 |
| Regular Market Previous Close | 40.46 |
| Regular Market Price | 39.12 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 424,938 |
| Return On Assets | -0.27617002 |
| Return On Equity | -0.43877 |
| Revenue Growth | -0.97 |
| Revenue Per Share | 0.002 |
| Sand P52 Week Change | 0.1966995 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 1 |
| Shares Outstanding | 78,529,532 |
| Shares Percent Shares Out | 0.0964 |
| Shares Short | 7,569,702 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 7,663,191 |
| Short Name | Celldex Therapeutics, Inc. |
| Short Percent Of Float | 0.1144 |
| Short Ratio | 7.85 |
| Source Interval | 15 |
| State | NJ |
| Symbol | CLDX |
| Target High Price | 100.0 |
| Target Low Price | 38.0 |
| Target Mean Price | 58.06667 |
| Target Median Price | 56.0 |
| Total Cash | 717,587,008 |
| Total Cash Per Share | 9.138 |
| Total Debt | 4,904,000 |
| Total Revenue | 158,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -4.35 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 31.11095 |
| Two Hundred Day Average Change | 8.009048 |
| Two Hundred Day Average Change Percent | 0.25743502 |
| Type Disp | Equity |
| Volume | 424,938 |
| Website | https://www.celldex.com |
| Zip | 8,827 |